{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01185080: Phase 2 Interventional Completed Allergic Rhinitis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03218826: Phase 1 Interventional Active, not recruiting Advanced Breast Carcinoma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
AZD-8186 is a potent and selective inhibitor of PI3Kβ and PI3Kδ with IC50 of 4 nM and 12 nM, respectively. AZD-8186 is currently in phase 1 clinical trials. Combination therapy using AZD-8186 with androgen deprivation results in long-lasting tumor regression, which persisted after treatment cessation.
Status:
Investigational
Source:
NCT01348139: Phase 2 Interventional Completed Asthma
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
USAN:LANABECESTAT CAMSYLATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01028040: Phase 1 Interventional Completed Healthy
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AZD-3043, a short-acting intravenous anesthetic/sedative agent. This drug was initially invented by Theravance and then developed by AstraZeneca as a positive allosteric modulator of the γ-aminobutyric acid type A (GABA(A)) receptor containing a metabolically labile ester moiety. Phase I clinical trials for use this compound in anesthesia was completed in Sweden and the UK, but further development was discontinued.
Status:
Investigational
Source:
NCT03327519: Not Applicable Interventional Terminated Asthma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT03554304: Phase 1 Interventional Completed QT/QTc Interval in Healthy Volunteers
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Zidebactam (also known as WCK 5107), a beta-lactam enhancer that belongs to the bicyclo-acyl hydrazide series. This drug inhibits the penicillin-binding protein and is participating in phase I clinical trial to treat the bacterial infection.
Status:
Investigational
Source:
NCT02155088: Phase 1 Interventional Completed Pancreatic Cancer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04488081: Phase 2 Interventional Recruiting COVID-19
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04473053: Phase 1/Phase 2 Interventional Recruiting COVID-19
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 is formulated for inhalation, which enables direct targeting the fibrotic tissue in the lungs, while minimizing systemic exposure. TD139 was initially developed by a team of scientists from Lund University, Sweden, and Edinburgh University, the UK. TD-139 is in phase I/II clinical trials for the treatment of idiopathic pulmonary fibrosis.
